MARKET

SYRS

SYRS

Syros Pharmaceut
NASDAQ
2.720
-0.070
-2.51%
Closed 16:07 03/30 EDT
OPEN
2.840
PREV CLOSE
2.790
HIGH
2.840
LOW
2.680
VOLUME
58.90K
TURNOVER
--
52 WEEK HIGH
14.30
52 WEEK LOW
2.670
MARKET CAP
55.22M
P/E (TTM)
-0.3630
1D
5D
1M
3M
1Y
5Y
RAPT Therapeutics, Repare Therapeutics, GlycoMimetics among biotechs to disclose exposure to Silicon Valley Bank
Seeking Alpha · 03/13 08:02
BRIEF-Syros Pharmaceuticals Inc - Discloses That, As Of March 10, 2023, It Has Two Deposit Accounts At Silicon Valley Bank
Reuters · 03/10 21:36
Syros Pharmaceuticals's Return On Capital Employed Overview
Benzinga · 03/08 14:46
Tesla To Rally Around 15%? Here Are 10 Other Analyst Forecasts For Friday
Benzinga · 03/03 13:16
Oppenheimer Maintains Outperform on Syros Pharmaceuticals, Lowers Price Target to $13
Benzinga · 03/03 12:16
H.C. Wainwright Remains a Buy on Syros Pharmaceuticals (SYRS)
TipRanks · 03/03 11:25
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $13 From $15, Maintains Outperform Rating
Oppenheimer Adjusts Syros Pharmaceuticals Price Target to $13 From $15, Maintains Outperform Rating
MT Newswires · 03/03 09:21
Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and COMPASS Pathways (CMPS)
TipRanks · 03/02 20:10
More
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company’s product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. It is also focused on the development for the treatment of multiple preclinical programs in oncology.

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.